11 17
1 15 15 11 3a
19 19 49 19 19 18

2a Cameron J. Koch, PhD

1 19 19 31 19 65 19 19 49 31 31 19 19 19 19 19 45
3b
19 19 19 1 1 1 1 2d
91 Cameron J. Koch photo 2f
42

Emeritus Professor of Radiation Oncology

18

74 Department: Radiation Oncology

11 13
7
1 1 5
1 18
e
25

Contact Information

c

3c 185 John Morgan Building
72 3620 Hamilton Walk
Philadelphia, PA 19104-6072 cf
Office: 215-898-0073
Fax: 215-898-0090
Email: kochc@pennmedicine.upenn.edu

13
5 e
1e

Publications

5a

Pubmed Link

b
9 e 9 12
1b

Education

d
    1d
  • 28 B.Sc. 63
    University of Waterloo, Ontario, Canada, 1968
    • 1d
  • 28 M.Sc. 63
    University of Waterloo, Ontario, Canada, 1969
    • 1d
  • 28 Ph.D. 63
    University of Waterloo, Ontario, Canada, 1972
    • 1a
b
b
1 5
1 1 1 2b

Description of Research Expertise

1e

RESEARCH INTERESTS:
48 Measurement of radioresistant hypoxic tumor cells in vivo using:
35 •immunohistochemistry and/or flow cytometry
1f •non-invasive imaging
27 •Quantification of tissue pO2
45 •Control and measurement of oxygen concentration and thiols
2f •Quantitative Fluorescence Microscopy
54 •Oxidative damage (primarily sulfydryl to disulfide) of DNA repair systems
55 •Effects of oxygen and oxygen radicals in biological or biochemical systems
3c •Development of fluorine-based PET imaging methods
27 •Automated chemical synthesis
71 •Mechanisms of action of radiation sensitizing and radiation protecting agents (survival or DNA damage)
49 •Models for competitive reactions of radiation modifying agents
4f •Metabolism of thiols and nitroheterocyclics (including cytotoxicity)
3b •Measurement of intracellular drug concentrations
5

1 1 1 1 1f

Selected Publications

5
    5
  • b7 Koch CJ : A Two-Component Assay for Hypoxia Incorporating Long-Term Nitroreduction and Short-Term DNA-Damage Allows Differentiation of the Three Hypoxia Sub-types 31 Rad Res : 72-87, May 10 2018
    • 5
  • c3 Koch CJ : Invited editorial for the paper by Silvoniemi et al. "Repeatability of tumor hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer." in this issue of EJNMMI 67 European Journal of Nuclear Medicine and Molecular Imaging 45(2) : 159-60, Feb 2018
    • 5
  • 107 Makvandi M, Lin L, Effron SS, Lieberman BP, Anderson R-C, Xu K, Li S-H, Lee S, Hou C, Pryma DA, Koch CJ, Mach RH : PARP-1 expression quantified by [18F]FluorThanatrace: a biomarker of response to PARP inhibition adjuvant to radiation therapy. 38 Cancer Biother Radiopharm Feb 2017
    • 5
  • 14d Ralph A. Pietrofesa, Anastasia Velalopoulou, Stacey L. Lehman, Evguenia Arguiri, Pantelis Solomides, Cameron J. Koch, Om P. Mishra, Constantinos Koumenis, Thomas J. Goodwin and Melpo Christofidou-Solomidou : Novel Double-Hit Model of Radiation and Hyperoxia-Induced Oxidative Cell Damage Relevant to Space Travel 31 Int J Mol Sci 17(6) Jun 2016
    • 5
  • 100 Evans SM, Putt M, Yang XY, Lustig RA, Martinez-Lage M, Williams D, Desai A, Wolf R, Brem S, Koch CJ. : Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. 3c J Neurooncol. 127(2) : 391-400, Apr 2016
    • 5
  • ff Lao Z, Kelly CJ, Yang XY, Jenkins WT, Toorens E, Ganguly T, Evans SM, Koch CJ. : Improved Methods to Generate Spheroid Cultures from Tumor Cells, Tumor Cells & Fibroblasts or Tumor-Fragments: Microenvironment, Microvesicles and MiRNA. 3b PLoS One. 10(7) : e0133895, Jul 24 2015
    • 5
  • 71 Koch CJ, Evans SM : Pharmacokinetic and pharmacodynamic modifiers of EF5 uptake and binding. 35 J Nucl Med. 56(4) : 653, Apr 2015
    • 5
  • 60 Koch CJ, Evans SM. : Optimizing hypoxia detection and treatment strategies. 3c Semin Nucl Med. 45(2) : 163-76, Mar 2015
    • 5
  • f0 Chang Q, Ornatsky OI, Koch CJ, Chaudary N, Marie-Egyptienne DT, Hill RP, Tanner SD, Hedley DW. : Single-cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry. 34 Int J Cancer. 136(5) Mar 1 2015
    • 5
  • fc Koch CJ, Lustig RA, Yang XY, Jenkins WT, Wolf RL, Martinez-Lage M, Desai A, Williams D, Evans SM. : Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients. 38 Transl Oncol. 7(6) : 752-8, Dec 2014
    • 6
1 1 19 1b
11 15 11 15 25 11 11 11 18
9 13